コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 s can be an innovative tool in management of retinal vein occlusion.
2 eneration (AMD), diabetic macular edema, and retinal vein occlusion.
3 cular degeneration, diabetic maculopathy, or retinal vein occlusion.
4 eovascularization in the pig model of branch retinal vein occlusion.
5 he treatment of macular edema due to central retinal vein occlusion.
6 cluded from the therapy approval studies for retinal vein occlusion.
7 and treatment of recurrent macular edema in retinal vein occlusion.
8 quantify macular edema in central and branch retinal vein occlusion.
9 improving visual acuity in participants with retinal vein occlusion.
10 efield angiogram images of eyes with central retinal vein occlusion.
11 edema secondary to either central or branch retinal vein occlusion.
12 egeneration or macular edema attributable to retinal vein occlusion.
13 oliferative diabetic retinopathy and central retinal vein occlusion.
14 ge-related macular degeneration, and central retinal vein occlusions.
15 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini
16 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co
18 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline
21 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre
22 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were
23 contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr
24 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio
27 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c
28 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne
29 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb
30 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.
33 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.
34 such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in
35 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.
36 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.
37 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.
38 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu
40 patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein
42 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high
43 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede
44 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal
45 natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana
47 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti
48 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c
54 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren
56 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ
57 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN
58 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha
60 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing
61 the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a
62 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc
63 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n
66 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus
67 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus
68 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec
69 To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen
74 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori
75 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch
78 and the absence of such a difference in the retinal vein occlusion group could be explained by edema
79 = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif
80 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo
82 to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than
83 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).
85 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA
88 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo
91 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran
92 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu
93 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n
94 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi
96 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography
97 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio
99 retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i
100 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P
102 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and
103 diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud
104 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),
105 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or
106 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi
108 Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive
109 the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of
110 the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients
112 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c
113 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate
114 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential
120 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis
121 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea
122 The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi
123 the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,
124 conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis
126 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei
127 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n
128 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit
131 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit
135 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age
139 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with
140 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal
141 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame
142 Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t
143 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。